Meet the METs
Researchers at Queen Mary, University of London have found that blocking endocytosis could treat MET-mutant cancers resistant to current treatments.1 Developing a safe way to inhibit the essential cellular process could prove challenging.
Endocytosis is a process by which the cell takes up extracellularmolecules including proteins for recycling or degradation. The process influences cell migration, survival and receptor signaling.2,3
In a paper published in Nature Cell Biology, Stéphanie Kermorgant and colleagues at the Barts Cancer Institute at Queen Mary, University of London have found support for the role of endocytosis in oncogenesis. The team has suggested that mutations in the c-Met proto-oncogene (MET; HGFR) might contribute to oncogenesis not only by inducing aberrant MET activation but also by increasing endocytosis of the